Seeking Alpha

Amarin (AMRN) says Phase 3 trials for vascepa met primary efficacy endpoints and significantly...

Amarin (AMRN) says Phase 3 trials for vascepa met primary efficacy endpoints and significantly reduced median concentrations of large very-low-density lipoprotein, total LDL, small LDL and total high-density lipoprotein particles and reduced VLDL particle size in patients with very high triglycerides. Shares +1.7% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs